Novel Organometallic Complex Prevents Metabolic Risk Factors in Male Adolescent Rats Consuming a High Fat Diet for 10 Weeks

Abstract

Listen

Translate article

The prevalence of metabolic syndrome has risen 35% since 2012 and over two‐thirds of Americans meet the criteria of obesity, dyslipidemia, hyperglycemia, insulin resistance and/or endothelial dysfunction. Treating metabolic syndrome is a challenge due to increasing consumption of energy dense foods and lack of compliance with dietary or exercise interventions. The aim of this study was to examine the effects of a novel organometallic complex (OMC) on these metabolic risk factors (obesity, hyperglycemia, dyslipidemia, endothelial dysfunction) in rats fed a high fat diet (HFD) for 10 weeks. Six‐week old male Sprague‐Dawley rats were divided into two dietary groups: standard chow or a HFD composed of 60% kcal from fat. Rats were further divided and treated with OMC in their drinking water at one of the following doses: vehicle (0 mg/mL), 0.6 mg/mL or 3.0 mg/mL. High fat feeding for 10 weeks increased body mass (n=5–6, p<0.05), adiposity (n=5–6, p<0.05), and fasting serum glucose concentrations (n=5, p<0.05) of vehicle‐treated rats. OMC did not prevent weight gain or adiposity in HFD‐fed animals. OMC‐treated HFD rats (3.0 mg/mL) had significantly lower fasting serum glucose concentrations compared to HFD‐vehicle rats (n=6, p<0.05) and OMC (3.0 mg/mL) significantly increased HDL‐c in chow‐fed rats (n=6, p<0.05). To examine endothelial dysfunction, isolated mesenteric resistance arteries (100–130 μm, inner diameter) were cannulated and pressurized to 60 mmHg in a vessel chamber. Arteries were then pre‐constricted to 50% of resting inner diameter with phenylephrine in the superfusate then exposed to increasing concentrations of acetylcholine (ACh, 0.0001–100μM). Low dose OMC promoted vasodilation at lower concentrations of ACh in chow‐fed rats compared to vessels isolated from matched vehicle‐treated animals (n=6, p<0.05). Consistent with prior studies, HFD rats developed impaired vasodilation (n=5, p<0.05), whereas both doses of OMC effectively increased endothelium‐dependent vasodilation (n=6, p<0.05). These findings suggest that OMC, particularly at the higher dose evaluated, effectively ameliorated risk factors associated with metabolic syndrome by attenuating hyperglycemia and improving endothelium‐dependent vasodilation in rats fed a HFD.Support or Funding InformationThis study was funded by a grant from Isagenix International, LLC.This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.